Response to Comments: MolDX: Molecular Biomarker Testing to Guide Targeted Therapy Selection in Rheumatoid Arthritis

The provided document (A59524) is a response-to-comments notice and does not contain specific coverage, limitation, documentation, or frequency criteria for molecular biomarker testing in rheumatoid arthritis. For actionable coverage criteria and requirements, refer to the MolDX LCD L39469 (effective 2023-10-15).

"This document is a response to public comments and does not specify coverage criteria for molecular biomarker testing to guide targeted therapy selection in rheumatoid arthritis; refer to MolDX Loc..."

Sign up to see full coverage criteria, indications, and limitations.